Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 308.7% in March

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 18,800 shares, an increase of 308.7% from the March 15th total of 4,600 shares. Based on an average trading volume of 5,600 shares, the days-to-cover ratio is presently 3.4 days. Currently, 0.2% of the company's stock are sold short.

Anebulo Pharmaceuticals Stock Performance

Shares of NASDAQ:ANEB traded down $0.23 during trading on Wednesday, hitting $2.60. The company's stock had a trading volume of 2,550 shares, compared to its average volume of 5,778. Anebulo Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $4.05. The stock's 50-day moving average price is $2.69 and its two-hundred day moving average price is $2.52. The company has a market capitalization of $66.64 million, a PE ratio of -6.19 and a beta of -1.00.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). On average, equities analysts predict that Anebulo Pharmaceuticals will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Anebulo Pharmaceuticals stock. Vanguard Group Inc. increased its position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Free Report) by 584.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 153,003 shares of the company's stock after purchasing an additional 130,659 shares during the period. Vanguard Group Inc. owned 0.60% of Anebulo Pharmaceuticals worth $370,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 28.40% of the company's stock.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.